JAC-Antimicrobial Resistance最新文献

筛选
英文 中文
Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and Candida species as determined by EUCAST broth microdilution. 欧盟肉汤微量稀释法测定的 5-氟胞嘧啶和念珠菌物种的野生型 MIC 分布和流行病学临界值。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-10-04 eCollection Date: 2024-10-01 DOI: 10.1093/jacamr/dlae153
Fatima Zohra Delma, Willem J G Melchers, Paul E Verweij, Jochem B Buil
{"title":"Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and <i>Candida</i> species as determined by EUCAST broth microdilution.","authors":"Fatima Zohra Delma, Willem J G Melchers, Paul E Verweij, Jochem B Buil","doi":"10.1093/jacamr/dlae153","DOIUrl":"10.1093/jacamr/dlae153","url":null,"abstract":"<p><strong>Objectives: </strong>EUCAST has established clinical breakpoints and epidemiological cutoff values (ECOFFs) for <i>Candida</i> spp. However, limited data are available for 5-flucytosine (5-FC). We assessed the <i>in vitro</i> susceptibility of 5-FC against a large collection of clinical <i>Candida</i> species using EUCAST methodology and determined the associated ECOFFs.</p><p><strong>Methods: </strong>A total of 5622 <i>Candida</i> isolates were collected from patients across the Netherlands between 2008 and 2024. 5-FC MICs were determined using the EUCAST microbroth dilution reference method. Furthermore, MICs were extracted from the EUCAST website. The MICs from this study and those extracted were used to determine ECOFFs and local ECOFFs (L-ECOFFs).</p><p><strong>Results: </strong>5-FC exhibited potent <i>in vitro</i> activity against <i>C. albicans</i>, <i>N. glabratus</i> and <i>C. parapsilosis,</i> while decreased susceptibility was observed for <i>C. tropicalis, Pichia species, K. marxianus, Y. lipolytica,</i> and <i>C. auris.</i> The ECOFFs (mg/L) and the percentages of WT isolates for 5-FC were: <i>C. albicans</i>: 0.5 (97.2%), <i>N. glabratus</i>: 0.5 (96.6%), <i>C. parapsilosis</i>: 0.5 (99.5%) and <i>P. kudriavzevii</i>: 8 (99.4%). The L-ECOFF (mg/L) and the percentages of WT isolates for 5-FC were: <i>C. dubliniensis</i>: 0.25 (96.8%), <i>C. tropicalis</i>: 0.25 (67.2%), <i>K. marxianus</i>: 0.25 (48.0%), <i>C. lusitaniae</i>: 0.25 (86.5%), <i>M. guillermondii</i>: 0.125 (95.9%) and <i>P. norvegiensis</i>: 8 (94.2%).</p><p><strong>Conclusions: </strong>5-FC remains a valuable drug to manage difficult-to-treat invasive <i>Candida</i> infections. <i>In vitro</i> susceptibility cannot be predicted based on species identification for most <i>Candida</i> species, but requires MIC-testing. ECOFFs will help to interpret the MICs to support treatment decisions.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae153"},"PeriodicalIF":3.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adopting prospective antimicrobial stewardship (AMS) practice in high-risk immunosuppressed groups: an urgent call to action in the era of antimicrobial resistance (AMR). 在高风险免疫抑制人群中采用前瞻性抗菌药物管理(AMS)实践:抗菌药物耐药性(AMR)时代的紧急行动呼吁。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-09-27 eCollection Date: 2024-10-01 DOI: 10.1093/jacamr/dlae145
S Agrawal, A Bapat, J Amos, E Howes, T Ashfield
{"title":"Adopting prospective antimicrobial stewardship (AMS) practice in high-risk immunosuppressed groups: an urgent call to action in the era of antimicrobial resistance (AMR).","authors":"S Agrawal, A Bapat, J Amos, E Howes, T Ashfield","doi":"10.1093/jacamr/dlae145","DOIUrl":"https://doi.org/10.1093/jacamr/dlae145","url":null,"abstract":"<p><p>Life-saving immunosuppressive treatments including intensive chemotherapy and bone marrow transplantation expose patients to a considerable risk of death from infection globally. With evolving AMR and transmission, this could spell disaster for patients across the world and society at large. Antimicrobial stewardship (AMS) and prompt appropriate management of potentially fatal, emergent infections are essential. It is now apparent that antibacterial prophylaxis in patients with haematological cancer may not provide survival benefit while simultaneously increasing risks for AMR carriage. With evolving AMR and increasing immunosuppressed populations across the world, we must institute robust AMS practices. Significant resources are used to combat the impact of AMR on immunosuppressed patients. For lower-middle income countries (LMICs) these resources may not be available and as such the impact caused by AMR is greater. By considering the patient journey holistically we consider risk of infection presented to patients temporally and geographically. A short-term and easy to implement approach of multi-disciplinary team (MDT)-style advance care planning for infection is advocated. Antimicrobials, when used appropriately, enable healthcare procedures to occur and exist. Indeed, the very future of clinical medicine will rely on this yet to be realized value of enablement. Proactive effort and change must occur across all sectors with holism; hence our impetus for convening a joint industry and clinical working group. With at-risk immunosuppressed groups being a sentinel for change, awareness and implementation of patient-centric actions for infection are essential and our recommendations serve as an urgent call to action.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae145"},"PeriodicalIF":3.7,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11428039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic characteristics of quinolone resistance in colistin-resistant Escherichia coli isolates from community residents in Ecuador and Vietnam. 厄瓜多尔和越南社区居民中分离出的耐大肠菌素大肠埃希氏菌耐喹诺酮类药物的基因组特征。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-09-26 eCollection Date: 2024-10-01 DOI: 10.1093/jacamr/dlae151
Hoa Thi Thanh Hoang, Mayumi Yamamoto, Yoshimasa Yamamoto
{"title":"Genomic characteristics of quinolone resistance in colistin-resistant <i>Escherichia coli</i> isolates from community residents in Ecuador and Vietnam.","authors":"Hoa Thi Thanh Hoang, Mayumi Yamamoto, Yoshimasa Yamamoto","doi":"10.1093/jacamr/dlae151","DOIUrl":"https://doi.org/10.1093/jacamr/dlae151","url":null,"abstract":"","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae151"},"PeriodicalIF":3.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance profiles of and associated risk factors for Pseudomonas aeruginosa nosocomial infection among patients at two tertiary healthcare facilities in Lusaka and Copperbelt Provinces, Zambia. 赞比亚卢萨卡省和铜带省两家三级医疗机构的病人对铜绿假单胞菌的抗菌药耐药性概况及铜绿假单胞菌院内感染的相关风险因素。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-09-16 eCollection Date: 2024-10-01 DOI: 10.1093/jacamr/dlae139
Patrice Ntanda Mukomena, Martin Simuunza, Sody Munsaka, Geoffrey Kwenda, Flavien Bumbangi, Kaunda Yamba, Josephine Kabwe, Jean-Marie Kayembe, John Bwalya Muma
{"title":"Antimicrobial resistance profiles of and associated risk factors for <i>Pseudomonas aeruginosa</i> nosocomial infection among patients at two tertiary healthcare facilities in Lusaka and Copperbelt Provinces, Zambia.","authors":"Patrice Ntanda Mukomena, Martin Simuunza, Sody Munsaka, Geoffrey Kwenda, Flavien Bumbangi, Kaunda Yamba, Josephine Kabwe, Jean-Marie Kayembe, John Bwalya Muma","doi":"10.1093/jacamr/dlae139","DOIUrl":"10.1093/jacamr/dlae139","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance (AMR) of pathogens such as <i>Pseudomonas aeruginosa</i> is among the top 10 threats to global health. However, clinical and molecular data are scarce in Zambia. We, therefore, evaluated the AMR profiles of <i>P. aeruginosa</i> nosocomial infections (NIs).</p><p><strong>Methods: </strong>A year-long hospital-based cross-sectional study was conducted at two large tertiary-level hospitals in Zambia. Patients with current or previous hospital contact were screened for NIs. The current study focused on patients diagnosed with <i>P. aeruginosa</i> NIs. Clinical specimens were collected for bacteriological culture, and PCR amplification of 16S rRNA gene fragments was performed on pure isolates. Hospital or NIs were defined as infections that arise during hospitalization, occurring at least 48 h after admission. The Kirby-Bauer's disk diffusion method was used to evaluate antibiotic resistance patterns. The association between AMR and risk factors was analysed using the χ<sup>2</sup> test.</p><p><strong>Results: </strong>Eight hundred and forty-one patients were screened, and clinical specimens were collected and analysed. Of them, 116 (13.7%) were diagnosed with <i>P. aeruginosa</i> NIs. The participants' ages ranged from 15 to 98 years, with a mean of 51 (SD ± 18). Catheter-associated urinary tract infections (57%) were the most common, followed by pressure sores (38.7%). <i>P. aeruginosa</i> isolates were primarily susceptible to amikacin, which had the highest resistance to FEP. We observed a high prevalence of multidrug resistance (73.6%). The AMR was associated with carbapenem-hydrolysing β-lactamase gene blaOXA-51 and surgical care.</p><p><strong>Conclusions: </strong>This study has demonstrated that multidrug-resistant <i>P. aeruginosa</i> is prevalent in hospitals in Zambia's Lusaka and Ndola districts and possibly countrywide.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae139"},"PeriodicalIF":3.7,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11403203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. 使用头孢妥珠治疗耐碳青霉烯类鲍曼不动杆菌感染的患者对头孢妥珠产生异抗性的频率。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-09-09 eCollection Date: 2024-10-01 DOI: 10.1093/jacamr/dlae146
Ryan K Shields, Ava J Dorazio, Giusy Tiseo, Kevin M Squires, Alessandro Leonildi, Cesira Giordano, Ellen G Kline, Simona Barnini, Alina Iovleva, Marissa P Griffith, Daria Van Tyne, Yohei Doi, Marco Falcone
{"title":"Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant <i>Acinetobacter baumannii</i> infections.","authors":"Ryan K Shields, Ava J Dorazio, Giusy Tiseo, Kevin M Squires, Alessandro Leonildi, Cesira Giordano, Ellen G Kline, Simona Barnini, Alina Iovleva, Marissa P Griffith, Daria Van Tyne, Yohei Doi, Marco Falcone","doi":"10.1093/jacamr/dlae146","DOIUrl":"10.1093/jacamr/dlae146","url":null,"abstract":"<p><strong>Background: </strong>Cefiderocol exhibits potent <i>in vitro</i> activity against carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAb), but this activity has not consistently translated to improved outcomes among patients. Cefiderocol heteroresistance, or the presence of a resistant subpopulation, has been proposed as one possible explanation. The objective of this study was to explore associations between heteroresistance and outcomes of patients with CRAb infections.</p><p><strong>Methods: </strong>Baseline CRAb isolates were collected from 27 consecutive patients in the USA and Italy. Cefiderocol susceptibility was tested by broth microdilutions in triplicate. Heteroresistance was defined by population analysis profiling in duplicate. Resistance mechanisms and strain relatedness were evaluated through comparative genomic analysis.</p><p><strong>Results: </strong>Overall, 59% of infecting CRAb isolates were identified as cefiderocol-heteroresistant; rates were higher among isolates from Italy (79%) than the USA (38%). The median Charlson Comorbidity and SOFA scores were 4 and 5, respectively; 44% of patients had pneumonia, which was the most common infection type. Rates of 28-day clinical success and survival were 30% and 73%, respectively. By broth microdilution, cefiderocol MICs ≥1 mg/L were associated with higher failure rates than MICs ≤0.5 mg/L (81% versus 55%). Rates of clinical failure were numerically higher among patients infected by cefiderocol-heteroresistant compared with susceptible CRAb (81% versus 55%). Whole-genome sequencing identified a premature stop codon in the TonB<i>-</i>dependent receptor gene <i>piuA</i> in six isolates, all of which were heteroresistant.</p><p><strong>Conclusions: </strong>This pilot study supports the hypothesis that cefiderocol treatment failure may be associated with higher MICs and/or the presence of heteroresistance. Further studies are needed to confirm these findings.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae146"},"PeriodicalIF":3.7,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic epidemiology and longitudinal sampling of ward wastewater environments and patients reveals complexity of the transmission dynamics of bla KPC-carbapenemase-producing Enterobacterales in a hospital setting. 通过对病房废水环境和患者进行基因组流行病学和纵向采样,揭示了医院环境中产蓝 KPC-碳青霉烯酶肠杆菌传播动态的复杂性。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-09-03 eCollection Date: 2024-10-01 DOI: 10.1093/jacamr/dlae140
N Stoesser, R George, Z Aiken, H T T Phan, S Lipworth, T P Quan, A J Mathers, N De Maio, A C Seale, D W Eyre, A Vaughan, J Swann, T E A Peto, D W Crook, J Cawthorne, A Dodgson, A S Walker
{"title":"Genomic epidemiology and longitudinal sampling of ward wastewater environments and patients reveals complexity of the transmission dynamics of <i>bla</i> <sub>KPC</sub>-carbapenemase-producing Enterobacterales in a hospital setting.","authors":"N Stoesser, R George, Z Aiken, H T T Phan, S Lipworth, T P Quan, A J Mathers, N De Maio, A C Seale, D W Eyre, A Vaughan, J Swann, T E A Peto, D W Crook, J Cawthorne, A Dodgson, A S Walker","doi":"10.1093/jacamr/dlae140","DOIUrl":"10.1093/jacamr/dlae140","url":null,"abstract":"<p><strong>Background: </strong>Healthcare-associated wastewater and asymptomatic patient reservoirs colonized by carbapenemase-producing Enterobacterales (CPE) contribute to nosocomial CPE dissemination, but the characteristics and dynamics of this remain unclear.</p><p><strong>Methods: </strong>We systematically sampled wastewater sites (<i>n</i> = 4488 samples; 349 sites) and patients (<i>n</i> = 1247) across six wards over 6-12 months to understand bla<sub>KPC</sub>-associated CPE (KPC-E) diversity within these reservoirs and transmission in a healthcare setting. Up to five KPC-E-positive isolates per sample were sequenced (Illumina). Recombination-adjusted phylogenies were used to define genetically related strains; assembly and mapping-based approaches were used to characterize antimicrobial resistance genes, insertion sequences (ISs) and Tn<i>4401</i> types/target site sequences. The accessory genome was evaluated in some of the largest clusters, and those crossing reservoirs.</p><p><strong>Results: </strong>Wastewater site KPC-E-positivity was substantial [101/349 sites (28.9%); 228/5601 (4.1%) patients cultured]. Thirteen KPC-E species and 109 strains were identified using genomics, and 24% of wastewater and 26% of patient KPC-E-positive samples harboured one or more strains. Most diversity was explained by the individual niche, suggesting localized factors are important in selection and spread. Tn<i>4401</i> + flanking target site sequence diversity was greater in wastewater sites (<i>P</i> < 0.001), which might favour Tn<i>4401</i>-associated transposition/evolution. Shower/bath- and sluice/mop-associated sites were more likely to be KPC-E-positive (adjusted OR = 2.69; 95% CI: 1.44-5.01; <i>P</i> = 0.0019; and adjusted OR = 2.60; 95% CI: 1.04-6.52; <i>P</i> = 0.0410, respectively). Different strains had different bla<sub>KPC</sub> dissemination dynamics.</p><p><strong>Conclusions: </strong>We identified substantial and diverse KPC-E colonization of wastewater sites and patients in this hospital setting. Reservoir and niche-specific factors (e.g. microbial interactions, selection pressures), and different strains and mobile genetic elements likely affect transmission dynamics. This should be considered in surveillance and control strategies.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae140"},"PeriodicalIF":3.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11369815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Aspergillus lentulus infections in Taiwan: clinical and environmental surveillance. 台湾新出现的曲霉菌感染:临床和环境监测。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-08-29 eCollection Date: 2024-08-01 DOI: 10.1093/jacamr/dlae138
Pao-Yu Chen, Chien-Ming Chao, Chwan-Yau Luo, Yau-Lin Tseng, Po-Lin Chen, Jun-Neng Roan, Wei-Lun Liu, Chien Chu, Chi-Jung Wu, Hsuan-Chen Wang, Ming-I Hsieh, Pui-Ching Choi, Yee-Chun Chen
{"title":"Emerging <i>Aspergillus lentulus</i> infections in Taiwan: clinical and environmental surveillance.","authors":"Pao-Yu Chen, Chien-Ming Chao, Chwan-Yau Luo, Yau-Lin Tseng, Po-Lin Chen, Jun-Neng Roan, Wei-Lun Liu, Chien Chu, Chi-Jung Wu, Hsuan-Chen Wang, Ming-I Hsieh, Pui-Ching Choi, Yee-Chun Chen","doi":"10.1093/jacamr/dlae138","DOIUrl":"https://doi.org/10.1093/jacamr/dlae138","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the prevalence and characteristics of <i>Aspergillus lentulus</i> clinical and environmental isolates in Taiwan.</p><p><strong>Methods: </strong><i>Aspergillus</i> isolates obtained from patients at three hospitals and from 530 soil samples across Taiwan were screened. <i>A. lentulus</i>, confirmed by calmodulin sequencing, was subjected to antifungal susceptibility testing and <i>cyp51A</i> analyses. Soil samples yielding <i>A. lentulus</i> were analysed for residues of 25 azole fungicides.</p><p><strong>Results: </strong>Nine <i>A. lentulus</i> isolates were identified, which included seven (1.2%, 7/601) isolates from three antifungal-naïve patients out of 601 <i>Aspergillus</i> section <i>Fumigati</i> clinical isolates and two (0.3%, 2/659) isolates out of 659 <i>Aspergillus</i> soil isolates. All isolates developed white colonies and failed to grow at 48°C. They were susceptible to anidulafungin but showed reduced susceptibility to amphotericin B (AmB), voriconazole and azole fungicides. One heart transplant recipient with proven invasive pulmonary aspergillosis (IPA) initially showed suboptimal response to voriconazole monotherapy but was cured with a combination of voriconazole-caspofungin, liposomal AmB (LAmB)-caspofungin, along with surgery, followed by voriconazole maintenance therapy. Among two critically ill patients with probable IPA, one survived with micafungin, while the other died of aspergillosis despite sequential isavuconazole and LAmB monotherapy. Clinical and environmental isolates sharing identical Cyp51A sequence are identified, matching the Cyp51A sequence of <i>A. lentulus</i> NIID0096. Flusilazole (0.0009 mg/kg) was detected in one soil sample.</p><p><strong>Conclusions: </strong>This study raises concerns about health threat posed by human pathogenic <i>A. lentulus</i> originating from natural environments and underscores the need for increased clinical and laboratory vigilance regarding <i>A. lentulus</i> infections.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 4","pages":"dlae138"},"PeriodicalIF":3.7,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use what you have: leveraging microbiology support to develop a cumulative antibiotic susceptibility report for antimicrobial stewardship at a district hospital in Ghana. 物尽其用:利用微生物学支持,为加纳一家地区医院的抗菌药物管理开发累积抗生素药敏报告。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-08-21 eCollection Date: 2024-08-01 DOI: 10.1093/jacamr/dlae129
Benedicta Bosu, Obed Kwabena Offe Amponsah, Phyllis Tawiah, Eric Darko, Nana Akua Abruquah, Annabella Bensusan Osafo, Emmanuel Sarkodie, Nana Bugyei Buabeng, Otridah Kapona, Alex Owusu-Ofori, Kwame Ohene Buabeng, Nana Kwame Ayisi-Boateng
{"title":"Use what you have: leveraging microbiology support to develop a cumulative antibiotic susceptibility report for antimicrobial stewardship at a district hospital in Ghana.","authors":"Benedicta Bosu, Obed Kwabena Offe Amponsah, Phyllis Tawiah, Eric Darko, Nana Akua Abruquah, Annabella Bensusan Osafo, Emmanuel Sarkodie, Nana Bugyei Buabeng, Otridah Kapona, Alex Owusu-Ofori, Kwame Ohene Buabeng, Nana Kwame Ayisi-Boateng","doi":"10.1093/jacamr/dlae129","DOIUrl":"10.1093/jacamr/dlae129","url":null,"abstract":"<p><strong>Background: </strong>Antibiograms provide effective support for empirical prescribing and antimicrobial stewardship programmes (ASPs). In low-resource settings, microbiology systems to develop antibiograms may be rudimentary or entirely lacking, which may place such facilities at a disadvantage. Notwithstanding this, facilities should use what they have to support ASPs to inform evidence-based antibiotic use. We report how an antibiogram was developed at a district hospital in Ghana to support its ASP.</p><p><strong>Methods: </strong>This was a retrospective analysis of antibiotic susceptibility testing (AST) results from the University Hospital, KNUST from January to December 2021. Data were exported from the hospital's laboratory information system to Microsoft Excel (Version 2013). IBM SPSS Statistics (Version 25) and Epi Info™ Version 7 were used for statistical analyses.</p><p><strong>Results: </strong>Overall, 1949 cultures were performed, 392 (20.1%) growing bacterial pathogens. Per the CLSI M39-A4 standard guidelines for antibiograms, only 360 of the bacterial isolates were used for the analyses. The majority of isolates were from urine (187; 51.9%). Among the Gram-negative bacteria, there was low susceptibility to amoxicillin/clavulanic acid (28%), cephalosporins (11%-35%) and meropenem (21%), but high susceptibility to amikacin (96%) and levofloxacin (81%). Low susceptibility of Gram-positive isolates to amoxicillin/clavulanic acid (34%), meropenem (34%) and penicillins (27%-35%) was also recorded, but high susceptibility to ciprofloxacin (80%), gentamicin (79%) and vancomycin (76%).</p><p><strong>Conclusion: </strong>High levels of bacterial resistance to cephalosporins and meropenem in the antibiogram were reported. This antibiogram highlighted the urgent need for pragmatic steps to curb antibiotic resistance through ASPs using strategies that positively improve clinicians' knowledge and prescribing practices.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 4","pages":"dlae129"},"PeriodicalIF":3.7,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Susceptibility of clinical isolates of novel pathogen Stenotrophomonas sepilia to novel benzoquinolizine fluoroquinolone levonadifloxacin. 新型病原体败血霉单胞菌临床分离株对新型苯喹嗪类氟喹诺酮左氧氟沙星的敏感性。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-08-21 eCollection Date: 2024-08-01 DOI: 10.1093/jacamr/dlae130
Surajit Chakraborty, Nishant Shekhar, Lipika Singhal, Rajneesh Singh Rawat, Ajay Duseja, Rahul K Verma, Kanika Bansal, Ivneet Kour, Sanjay Biswas, Ekadashi Rajni, Suneeta Sahu, Prabhu B Patil, Vikas Gautam
{"title":"Susceptibility of clinical isolates of novel pathogen <i>Stenotrophomonas sepilia</i> to novel benzoquinolizine fluoroquinolone levonadifloxacin.","authors":"Surajit Chakraborty, Nishant Shekhar, Lipika Singhal, Rajneesh Singh Rawat, Ajay Duseja, Rahul K Verma, Kanika Bansal, Ivneet Kour, Sanjay Biswas, Ekadashi Rajni, Suneeta Sahu, Prabhu B Patil, Vikas Gautam","doi":"10.1093/jacamr/dlae130","DOIUrl":"10.1093/jacamr/dlae130","url":null,"abstract":"<p><strong>Background: </strong><i>Stenotrophomonas sepilia</i>, identified in 2021, is part of the <i>Stenotrophomonas maltophilia</i> complex (Smc) and shares high genomic identity with <i>S. maltophilia</i>. Resistance to levofloxacin, the recommended fluoroquinolone for <i>S. maltophilia</i>, is being increasingly reported. Recent studies indicate that levonadifloxacin, a novel benzoquinolizine, may be more effective. This study evaluates the antimicrobial efficacy of levofloxacin and levonadifloxacin against clinical isolates of <i>S. sepilia</i>.</p><p><strong>Objectives: </strong>To assess the antibacterial effectiveness of levofloxacin and levonadifloxacin against novel pathogen <i>S. sepilia.</i></p><p><strong>Methods: </strong>A total of 116 <i>S. maltophilia</i> isolates, identified by MALDI-TOF MS, were collected from five centres across India. <i>S. sepilia</i> was confirmed by PCR using primers targeting a unique genomic sequence (NCBI accession number LXXZ00000000.1). Minimum inhibitory concentrations (MICs) of levonadifloxacin and levofloxacin were determined by using the microbroth-dilution method and Etest as per CLSI guidelines. The levofloxacin breakpoint was used to interpret MICs of levonadifloxacin.</p><p><strong>Results: </strong>Among a total of 116 circulating <i>S. maltophilia</i> isolates collected, 46 were identified as <i>S. sepilia</i>, representing a prevalence rate of (∼40%), thus highlighting its significance as an important pathogen within the Smc. Both levofloxacin and levonadifloxacin demonstrated a 98% inhibition rate against the 46 <i>S. sepilia</i> tested. Only one <i>S. sepilia</i> isolate resistant to levofloxacin showed intermediate susceptibility to levonadifloxacin, which consistently had lower MICs.</p><p><strong>Conclusions: </strong>Levofloxacin and levonadifloxacin show similar susceptibility rates against <i>S. sepilia</i>, with levonadifloxacin exhibiting lower MICs. Further studies are required to establish clinical utility of levonadifloxacin in managing these infections.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 4","pages":"dlae130"},"PeriodicalIF":3.7,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The bla NDM-1 and mcr-1 genes coexist in Escherichia coli strain isolated from public trash cans. 从公共垃圾桶中分离出的大肠埃希菌菌株中同时存在 bla NDM-1 和 mcr-1 基因。
IF 3.7
JAC-Antimicrobial Resistance Pub Date : 2024-08-20 eCollection Date: 2024-08-01 DOI: 10.1093/jacamr/dlae132
Xiaoqian Long, Jie Li, Hua Yang, Yuehua Gao, Jiangang Ma, Xiaoqun Zeng, Biao Tang
{"title":"The <i>bla</i> <sub>NDM-1</sub> and <i>mcr-1</i> genes coexist in <i>Escherichia coli</i> strain isolated from public trash cans.","authors":"Xiaoqian Long, Jie Li, Hua Yang, Yuehua Gao, Jiangang Ma, Xiaoqun Zeng, Biao Tang","doi":"10.1093/jacamr/dlae132","DOIUrl":"10.1093/jacamr/dlae132","url":null,"abstract":"","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 4","pages":"dlae132"},"PeriodicalIF":3.7,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信